Skip to main content

Advertisement

Table 3 Number of adverse events reported between 1 year and 2 years

From: Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)

  Early remission n = 387 Arm 1 n = 83 Arm 2 n = 78 OOP n = 50
Patients with AE*, n (%) 205/387 (53 %) 53/83 (64 %) 52/78 (67 %) 27/50 (54 %)
Total number of AE 408 129 109 58
Cardiovascular 25 5 8 4
Pulmonary 17 5 2 2
Gastrointestinal 67 16 14 12
GI complaints 8 2 2
 Nausea/emesis 23 2 4 4
 Increased liver enzymes 15 7 3 4
 Other 21 5 5 4
Neuro-psychiatric 37 5 7 3
 Headache 14 4 1
 Dizziness 7 1 1
 Mood disorders 4 1
 Other 12 4 3
Urogenital 7 3 2 3
Skin/mucous membranes 45 18 15 3
 Rash 19 8 5
 Hair loss/thinning 4 1 1 1
 Sicca complaints 3 1
 Eczema 3 1
 Other 16 8 9 1
Infections 106 38 41 18
 Upper airway tract 29 11 16 10
 Gastrointestinal 4 1 2
 Skin/mucosa 14 2 4 2
 Pneumonia/bronchitis 9 1 1 1
 Urinary tract 15 7 5 1
 Influenza/unspecified fever 25 10 6 1
 Other 10 6 9 1
Trauma/injury 13 5 2 3
Infusion reaction 3 1
Malaise 9 5 1 1
Surgical procedures without hospitalization 13 5 4 1
Other 65 23 12 8
  1. *One or more adverse events possible per patient. OOP outside of protocol, AE adverse events, GI gastrointestinal